Conference Coverage
Videos
NewsNetwork
OncLive® TV
Peer Exchange
Insights
Attend An Event
State of the Science Summit
Regional Seminar Series
PER Conferences
Giants of Cancer Care
ISGIO
Webinars
OncLive Community
SPECIALTY TOPICS
CURRENTLY VIEWING
All Specialties
Breast Cancer
Multiple Myeloma
Lung Cancer
Immuno-Oncology News
Gynecologic Oncology
Gastrointestinal Cancer
Colorectal Cancer
Ovarian Cancer
Prostate Cancer
Precision Medicine in Oncology®
Neoadjuvant HER2+
More >>

Latest from The Tisch Cancer Institute

Dr. Hirsch on the Expansion of Molecular Testing in Lung Cancer
Fred R. Hirsch, MD, PhD, discusses the expansion of molecular testing in lung cancer.
Dr. Oh on Choosing AR-Targeted Therapy Versus Chemotherapy in mHSPC
William K. Oh, MD, discusses factors to consider when choosing a treatment for patients with metastatic hormone-sensitive prostate cancer. 
 
Dr. Cho on Investigational BiTE Therapies in Multiple Myeloma
Hearn Jay Cho, MD, PhD, discusses investigational bispecific T-cell engager therapies in multiple myeloma.
Dr. Jagannath on the Safety Profile of Selinexor in Multiple Myeloma
Sundar Jagannath, MD, discusses the use and toxicity profile of selinexor in multiple myeloma treatment.
Dr. Chari on Using Selinexor in Multiple Myeloma Treatment
Ajai Chari, MD, discusses the use of selinexor in multiple myeloma treatment.
Dr. Parekh on Using Genomics in Multiple Myeloma Treatment
Samir Parekh, MBBS, discusses using genomics to treat patients with multiple myeloma.
Mapping Multiple Myeloma Advances in NYC
We traveled to New York City, New York, for a State of the Science Summit™ on Multiple Myeloma, which featured insights from the faculty from the Mount Sinai Hospital.
Genomic Testing Puts Myeloma Paradigm on Personalized Path
Samir Parekh, MBBS, highlights ongoing research regarding personalized medicine for multiple myeloma.
Next Page >>
Inside Oncology
View more videos >>
FDA Approval of a Biosimilar, Promising Data in Myeloma and GBM, and More
FDA Approval of a Biosimilar, Promising Data in Myeloma and GBM, and More
Update on NDA in GIST, Promising Data in Lung Cancer, KRAS G12C-Mutant Cancers, and AML, and European Approval in RCC
Update on NDA in GIST, Promising Data in Lung Cancer, KRAS G12C-Mutant Cancers, and AML, and European Approval in RCC
FDA Approvals in Ovarian Cancer and for MEC Chemo, Promising Data in Lung Cancer, and More
FDA Approvals in Ovarian Cancer and for MEC Chemo, Promising Data in Lung Cancer, and More
Publication Bottom Border
Border Publication
 
x